

Charles E. Stoopack M.D. FACOG

3240 Venado St • Carlsbad, CA 92009

Phone: 760-845-1692 • Fax: 760-944-1333 • E-Mail: cstoopack@ucsd.edu

Education

M.D. New York Medical College, Valhalla, N.Y., 1980

Michaelin Scholarship Recipient

Alpha Omega Alpha Honor Society

B.S. Cornell University, Ithaca, N.Y., Graduation with Distinction, 1976

New York State Regents Scholarship recipient

Postgraduate Training

- Internship and Residency: 1980-1984
University of California, San Diego Dept. of Reproductive Medicine

Board Certification

- American Board of Obstetrics and Gynecology 1987
- Recertified Annually 2023

License

- California Medical License: G45525

Fellowship

- Fellow and Diplomat: American College of OB/GYN

Publications

- Tri City Medical Center, Cancer Program Annual Report 1993
Cervical Carcinoma
- Tri City Medical Center, Cancer Program Annual Report 1990
Endometrial Carcinoma

Hospital Appointments

- Tri City Medical Center, Chairman, Dept. OB/GYN 2003-2004
- Tri City Medical Center, Chairman, Dept. OB/GYN 1998-2000

OB/GYN Quality Assurance Committee

- Tri City Medical Center, Chairman, Dept. OB/GYN 1988-1989

Academic Appointments

- Assistant Professor/Health Sciences Clinical Instructor 2011-Present
UC San Diego School of Medicine

Voluntary Clinical Instructor 2009- 2011
UC San Diego

Private Practice

- North Coast Women's Care Medical Group, Inc. 1992-2008
CEO and President
- Stoopack and Fenton, AGP 1989-1992
CEO and President

Board Positions

- Medvec International GmbH 2006 - Present
Chief Medical Officer

Recognitions

- The Award for Excellence in Teaching 2018
UC San Diego School of Medicine
- Excellence in Teaching Award Nominee 2012, 2015
UC San Diego School of Medicine
- Top Doctors of San Diego County 2004
San Diego Magazine (selected by peers) 1999
- Guide to Top Doctors
Center for the Study of Services (selected by peers)

Research Experience

Please see attached

NORTH COAST WOMEN'S CARE RESEARCH FACILITY EXPERIENCE

Jan 2007-2012

Clinical Study Protocol #511.84

A Twelve Month, Open-label, Safety Trial of XXX 50 milligrams to 100 milligrams Daily in Women with Hypoactive Sexual Desire Disorder

Principal Investigator: Douglas K. Fenton, MD

Subinvestigators: Christine Z. Brody, MD
Charles E. Stoopack, MD
Ross M. Langley, MD
Lynne Calkins CRNP
Rumiko Harkness CRNP

Study Coordinator: Mary K. Fenton, RN, MN

Target Enrollment: 15 patients

Screened: 28

Enrolled: 28

Jan 2007-2012

Clinical Study Protocol #108933 HPV 010

A Phase IIIb, Observer-blind, Randomized, Multicenter Study with Two Parallel Groups to Compare the Immunogenicity of XXX Vaccine versus Merck's Gardasil Vaccine when administered Intramuscularly According to a 3-dose Schedule in Healthy Females 18-45 years of age.

Principal Investigator: Douglas K. Fenton, MD

Subinvestigators: Christine Z. Brody, MD
Charles E. Stoopack, MD
Ross M. Langley, MD
Lynne Calkins CRNP

Study Coordinator: Mary K. Fenton, RN MN

Target Enrollment: 75 patients

Screened: 40 patients

Enrolled: 40 patients

Dec. 2006-Apr. 2007

Clinical Study Protocol #FENHYDPAI4003

A Multicenter, Double-blind, Randomized, Placebo-controlled, Multiple-dose, Parallel Group Study to Determine Time of Onset of Pain Relief Using Standard Regimen of Morphine via Intravenous PCA following Total Abdominal Hysterectomy

Principal Investigator: Christine Z. Brody, MD

Subinvestigators: Charles E. Stoopack, MD

Douglas K. Fenton, MD

Ross M. Langley, MD

Lynne Calkins CRNP

Study Coordinator: Mary K. Fenton, RN, MN

Target Enrollment: 5 patients

Screened: 6 patients

Enrolled: 5 patients

Dec 2006-Feb. 2008

Clinical Study Protocol #DR-ASC-201

A Prospective, Multicenter, Double-blind, Randomized, Study to Evaluate Bleeding Patterns in Women Using One of Three Different Ascending EE Dose Extended-Cycle (91-Day) Oral Contraceptive Regimens (XXX) Compared to Seasonale Oral Contraceptive Regimen

Principal Investigator: Christine Z. Brody, MD

Subinvestigators: Charles E. Stoopack, MD

Douglas K. Fenton, MD

Ross M. Langley, MD

Lynne Calkins CRNP

Study Coordinator: Shambra Rodriguez MA

Target Enrollment: 15 patients

Screened: 15 patients

Enrolled: 10 patients

July 2006-present Clinical Study Protocol #511.70

A Twenty-Four week, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of X mg of XXX twice daily and X mg once and twice daily in Premenopausal Women with Hypoactive Sexual Desire Disorder in North America

Principal Investigator: Charles E. Stoopack, MD

Subinvestigators: Christine Z. Brody, MD

Douglas K. Fenton, MD

Ross M. Langley, MD

Lynne Calkins CRNP

Rumiko Harkness CRNP

Study Coordinator: Mary K. Fenton, RN, MN

Target Enrollment: 18 patients

Screened: 36 patients

Enrolled: 36 patients

July 2006-July 2007 Clinical Study Protocol #DR-DZL-201

A Phase 2, Multicenter, Double-blinded, Randomized, Placebo-controlled Study to Evaluate Two Doses of XXX Vaginal Ring for the Management of Moderate to Severe Endometriosis-Related Non-menstrual Pelvic Pain

Principal Investigator: Christine Z. Brody, MD

Subinvestigators: Charles E. Stoopack, MD

Douglas K. Fenton, MD

Ross M. Langley, MD

Lynne Calkins CRNP

Study Coordinator: Mary K. Fenton, RN, MN

Target Enrollment: 3 patients* (*Sponsor closed study prematurely)

Screened: 16 patients

Enrolled: 1 patient

July-December 2006 Clinical Study Protocol# 3142A2-203-WW

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of X mg and X mg Doses of XXX on the Reduction of Symptoms Associated with Endometriosis during Treatment and

Post-Treatment in Reproductive-Aged Women

Principal Investigator: Christine Z. Brody, MD
 Subinvestigators: Charles E. Stoopack, MD
 Douglas K. Fenton, MD
 Ross M. Langley, MD
 Lynne Calkins CRNP
 Study Coordinator: Mary K. Fenton, RN, MN
 Target Enrollment: 3 patients
 Screened: 5 patients
 Enrolled: 3 patients* (*Sponsor closed study prematurely)

April 2006-Dec 2006 Clinical Study Protocol #1VIT06011

Comparison of the Safety and Efficacy of a Unique Intravenous Iron Preparation XXX versus Oral Iron in Subjects who Display Postpartum Anemia

Principal Investigator: Christine Z. Brody, MD
 Subinvestigators: Charles E. Stoopack, MD
 Douglas K. Fenton, MD
 Ross M. Langley, MD
 Lynne Calkins CRNP
 Study Coordinator: Mary K. Fenton, RN, MN
 Target Enrollment: 10 patients
 Screened: 22 patients
 Enrolled: 14 patients

March 2006-Nov. 2007 Clinical Study Protocol #3115A1-304-WW

A Double-Blind, Randomized, Placebo and Active Controlled Efficacy and Safety Study of XXX for Prevention of Endometrial Hyperplasia and Prevention of Osteoporosis in Postmenopausal Women

Principal Investigator: Douglas K. Fenton, MD
 Subinvestigators: Christine Z. Brody, MD
 Charles E. Stoopack, MD
 Ross M. Langley, MD
 Lynne Calkins CRNP
 Study Coordinator: Mary K. Fenton, RN MN
 Target Enrollment: 10 patients
 Enrolled: 20 patients

Oct-Dec 2005**Clinical Study Protocol #DOV-075-024**

A Multi-center, Double-blinded, Placebo-controlled, Randomized Study of XXX for the Treatment of Post-operative Pain Following Vaginal Hysterectomy

Principal Investigator: Charles E. Stoopack, MD

Subinvestigators: Christine Z. Brody, MD
 Douglas K. Fenton, MD
 Ross M. Langley, MD
 Lynne Calkins CRNP

Study Coordinator: Mary K. Fenton, RN, MD

Target Enrollment: 8 patients

Screened: 4 patients

Enrolled: *2 patients (*Sponsor closed study prematurely)

May 2005-Feb 2006**Clinical Study Protocol #1VIT03001**

Comparison of the Safety and Efficacy of a Unique Intravenous Iron Preparation (XXX) versus Oral Iron in Subjects Who Display Postpartum Anemia

Principal Investigator: Christine Z. Brody, MD

Subinvestigators: Charles E. Stoopack, MD
 Douglas K. Fenton, MD
 Ross M. Langley, MD
 Lynne Calkins CRNP

Study Coordinator: Mary K. Fenton, RN, MN

Target Enrollment: 10 patients

Screened: 13 patients

Enrolled: *7 patients (*Add-on Site)

May-Sept 2005**Clinical Study Protocol #1VIT04003**

Comparison of the Safety and Efficacy of a Unique Intravenous Iron Preparation (XXX) versus Oral Iron in the Treatment of Iron Deficiency Anemia Secondary to Heavy Uterine Bleeding

Principal Investigator: Christine Z. Brody, MD

Subinvestigators: Charles E. Stoopack, MD
Douglas K. Fenton, MD
Ross M. Langley, MD
Lynne Calkins CRNP
Study Coordinator: Mary K. Fenton, RN, MN
Target Enrollment: 10 patients
Screened: 22 patients
Enrolled: 10 patients

May 2004 – April 2005 Clinical Study Protocol # CAPSS 320

Comparison of the Safety and Efficacy of Patient Controlled Analgesia

Delivered by XXX versus Morphine IV Pump for Pain Management

After Non-emergent Abdominal Surgery

Principal Investigator: Christine Z. Brody, MD
Subinvestigators: Charles E. Stoopack, MD
Douglas K. Fenton, MD
Ross M. Langley, MD
Darcey B. Perlman, MD
Study Coordinator: Mary K. Fenton, RN, MN
Target Enrollment: 12 patients
Screened: 59 patients
Enrolled: 48 patients

May-Aug 2004 Clinical Study Protocol #11658-001

A Prospective Evaluation of the Burden of Post-Operative Ileus and Opioid Bowel Dysfunction in Patients Undergoing Abdominal Surgery

Principal Investigator: Douglas K. Fenton, MD
Subinvestigators: Christine Z. Brody, MD
Charles E. Stoopack, MD
Ross M. Langley, MD
Darcey B. Perlman, MD
Study Coordinator: Mary K. Fenton, RN MN
Target Enrollment: 8 patients
Screened: 8 patients
Enrolled: 8 patients

2004 Clinical Study Protocol #BT0300C1-300-USA
Comparison Study of the Safety and Efficacy of a Single Dose of XXX
versus a Single Dose of XXX in the Treatment of Vaginal Candidiasis

Principal Investigator: Christine Z. Brody, MD
Subinvestigators: Charles E. Stoopack, MD
Douglas K. Fenton, MD
Ross M. Langley, MD
Darcey B. Perlman, MD

2004 Clinical Study Protocol #2004031
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group,
Multicenter, 52 week study to evaluate the efficacy and safety of
XXX in menopausal women with low libido not receiving systemic
estrogen or estrogen progestin therapy

Subinvestigators: Christine Z. Brody, MD
Charles E. Stoopack, MD
Douglas K. Fenton, MD
Ross M. Langley, MD
Darcey B. Perlman, MD

2003-2004 Clinical Study Protocol #CFAM810A US07
An Open Label, Single-Arm Multicenter study to evaluate the safety and
efficacy of XXX in the episodic treatment of Recurrent Genital Herpes,
XXX for 5 days, and in the suppressive treatment of Recurrent Genital
Herpes, XXX for 6 months

Principal Investigator: Charles E. Stoopack, MD
Subinvestigators: Christine Z. Brody, MD
Douglas K. Fenton, MD
Ross M. Langley, MD
Darcey B. Perlman, MD
Study Coordinator: Mary K. Fenton, RN, MN

2001-2003

Clinical Study Protocol #14CL306

A Multicenter Phase III, Double-blind, Placebo Controlled Study of XXX in Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus in subjects undergoing Total Abdominal Hysterectomy

Principal Investigator: Christine Z. Brody, MD

Subinvestigators: Charles E. Stoopack, MD

Douglas K. Fenton, MD

Ross M. Langley, MD

2000-2002

Clinical Study Protocol #14CL302

A Multicenter Phase III, Double-blind, Placebo Controlled Study of XXX in Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus

Principal Investigator: Christine Z. Brody, MD

Subinvestigators: Charles E. Stoopack, MD

Douglas K. Fenton, MD

Ross M. Langley, MD

